Evidence map›Paper›PMID 39186368›Full record

ArticleJournal of medical Internet research2024

Creating a Modified Version of the Cambridge Multimorbidity Score to Predict Mortality in People Older Than 16 Years: Model Development and Validation.

Debasish Kar, Kathryn S Taylor, Mark Joy, Sudhir Venkatesan, Wilhelmine Meeraus, Sylvia Taylor, Sneha N Anand, Filipa Ferreira, Gavin Jamie, Xuejuan Fan and 1 more

Abstract readValidation Study
In one paragraph

Article in Journal of medical Internet research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. How to assess multimorbidity: a systematic review.Frontiers in public health · 2025
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Debasish Kar *Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-1524-1312
Kathryn S Taylor *Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-6589-5456
Mark JoyNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-4974-3724
Sudhir VenkatesanMedical & Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca PLC, Cambridge, United Kingdom.ORCID 0000-0002-2093-5781
Wilhelmine MeerausMedical Evidence, Vaccines and Immune Therapies, AstraZeneca PLC, Cambridge, United Kingdom.ORCID 0000-0001-7476-8061
Sylvia TaylorMedical Evidence, Vaccines and Immune Therapies, AstraZeneca PLC, Cambridge, United Kingdom.ORCID 0000-0001-7803-0611
Sneha N AnandNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-0538-3974
Filipa FerreiraNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-7717-8486
Gavin JamieNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-9147-7784
Xuejuan FanNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-0165-8344
Simon de LusignanNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-8553-2641

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNo single multimorbidity measure is validated for use in NHS (National Health Service) England's General Practice Extraction Service Data for Pandemic Planning and Research (GDPPR), the nationwide primary care data set created for COVID-19 pandemic research. The Cambridge Multimorbidity Score (CMMS) is a validated tool for predicting mortality risk, with 37 conditions defined by Read Codes. The GDPPR uses the more internationally used Systematized Nomenclature of Medicine clinical terms (SNOMED CT). We previously developed a modified version of the CMMS using SNOMED CT, but the number of terms for the GDPPR data set is limited making it impossible to use this version.

objectiveWe aimed to develop and validate a modified version of CMMS using the clinical terms available for the GDPPR.

methodsWe used pseudonymized data from the Oxford-Royal College of General Practitioners Research and Surveillance Centre (RSC), which has an extensive SNOMED CT list. From the 37 conditions in the original CMMS model, we selected conditions either with (1) high prevalence ratio (≥85%), calculated as the prevalence in the RSC data set but using the GDPPR set of SNOMED CT codes, divided by the prevalence included in the RSC SNOMED CT codes or (2) conditions with lower prevalence ratios but with high predictive value. The resulting set of conditions was included in Cox proportional hazard models to determine the 1-year mortality risk in a development data set (n=500,000) and construct a new CMMS model, following the methods for the original CMMS study, with variable reduction and parsimony, achieved by backward elimination and the Akaike information stopping criterion. Model validation involved obtaining 1-year mortality estimates for a synchronous data set (n=250,000) and 1-year and 5-year mortality estimates for an asynchronous data set (n=250,000). We compared the performance with that of the original CMMS and the modified CMMS that we previously developed using RSC data.

resultsThe initial model contained 22 conditions and our final model included 17 conditions. The conditions overlapped with those of the modified CMMS using the more extensive SNOMED CT list. For 1-year mortality, discrimination was high in both the derivation and validation data sets (Harrell C=0.92) and 5-year mortality was slightly lower (Harrell C=0.90). Calibration was reasonable following an adjustment for overfitting. The performance was similar to that of both the original and previous modified CMMS models.

conclusionsThe new modified version of the CMMS can be used on the GDPPR, a nationwide primary care data set of 54 million people, to enable adjustment for multimorbidity in predicting mortality in people in real-world vaccine effectiveness, pandemic planning, and other research studies. It requires 17 variables to produce a comparable performance with our previous modification of CMMS to enable it to be used in routine data using SNOMED CT.

Indexed as

COVID-19MultimorbidityAdolescentAdultAgedAged, 80 and overEnglandFemaleHumansMaleMiddle AgedPandemicsSARS-CoV-2Systematized Nomenclature of MedicineYoung Adultcalibrationcomputerized medical recordsCOVID-19discriminationmultimorbiditypandemicspredictive modelprevalencesystematized nomenclature of medicinesystems

Identifiers

PMID39186368
PMCPMC11384182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.